Medical Oncologist, Gynaecological and Lung Cancers, Carcinoma of Unknown Primary. Views are entirely my own
Joined September 2016
- Tweets 1,115
- Following 381
- Followers 1,206
- Likes 3,844
213 Photos and videos
@Qantas you are just the worst! Charge my credit card but not completed a flight booking. Spoken to 4 different consultants on the help line with no resolution. Most don’t speak English well and tell conflicting stories. So frustrating
1
7
390
I follow their instructions and call back only have to start from the beginning every time - now on hold yet again. What is the point of trying to be a frequent flyer with @Qantas??
1
2
233
6 Nov 2025
Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!
6 Nov 2025
#IGCS2025 Congratulations Dr. Hayes!! Even though exercise did not improve PFS or OS or physical well being it was an amazing study and effort!! 🥰❤️🥰 still hopeful that exercise programs can improve outcomes for some. Still work to do!!
1
2
8
1,052
6 Nov 2025
The discussant @ShannonWestin intrigued by the OS curves in the ECHO trial which although not significant currently may improve with time. Also pointing out that PFS was excellent in both arms.
6 Nov 2025
Well done on a great presentation of the @anzgog ECHO trial by Sandy Hayes at #IGCS2025 this am. Why were the results different from the Challenge trial? Reassuring for women having chemo for ovarian cancer to know that if they don’t feeling like walking every day it is ok!
2
4
366
6 Nov 2025
Great way to start Day 2 of #IGCS2025 with a Run for Hope to raise funds for Gynae cancer!
3
6
316
Linda Mileshkin retweeted
6 Nov 2025
Peter Mac has joined @AAMRI_Aus and other research institutes around Australia to support calls for more medical research funding. The 'Half the Funding, Half the Future' campaign wants more funds for research into things like the fight against cancer - bit.ly/3LlUS9X
3
7
533
5 Nov 2025
People shouldn’t have to choose inferior treatments for women with Gynaecological cancers because of lack of access to working radiotherapy machines and staff to operate them in Africa - as as being highlighted at the #IGCS2025 meeting in Cape Town
5
9
484
4 Nov 2025
Dr Jason Wright from @greenjrnl encouraging people to keep trying to get your paper published even if initially rejected. Don’t perseverate, consider the peer reviewer comments, just revise and re-submit! @IGCSociety #igcs2025
2
6
308
4 Nov 2025
So excited to be in Cape Town for the start of the @IGCSociety Annual Global meeting. Starting with a journal publication workshop highlighting the discrepancy between where most Gynae cancers occur vs where publications come from
1
8
196
Linda Mileshkin retweeted
6 Sep 2025
✨ There’s still time to register! Don’t miss the chance to join us in beautiful Cape Town for IGCS 2025 — a city of culture, diversity, and breathtaking landscapes. 🌍✈️ #IGCS2025 #CapeTown
igcsmeeting.com/register-now…
4
6
585
Linda Mileshkin retweeted
6 Jun 2025
Here in Canada, Prof. Senan reminds us of an urban myth. 🇨🇦 #SABRCAN25 ascopubs.org/doi/10.1200/JCO…
2
20
82
11,040
6 Jun 2025
Really proud for @ANZGOG and #APGOT to have been involved with this practice changing study for women with platinum resistant ovarian cancer! @PeterMacCC
2 Jun 2025
📄 Presented at #ASCO25
“Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial”
hubs.ly/Q03q9P6H0
1️⃣ Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival
2️⃣ Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
ALT Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival
ALT Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
1
2
14
650
Linda Mileshkin retweeted
2 Jun 2025
📄 Presented at #ASCO25
“Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial”
hubs.ly/Q03q9P6H0
1️⃣ Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival
2️⃣ Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
ALT Figure 2: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for progression-free survival
ALT Figure 3: Efficacy findings comparing relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy for the interim overall survival analysis
3
15
7,224
Linda Mileshkin retweeted
21 May 2025
🧬 New research in @Nature shows advanced genomic testing can help more people with #Cancer of Unknown Primary get targeted treatment & identify where their cancer started.
Led by @GenCancerCentre a joint venture of @unimelb & @PeterMacCC.
🔗 petermac.org/about-us/news-a…
9
25
1,632
Linda Mileshkin retweeted
28 Feb 2025
U.S. Sees Huge Drop in Cervical Precancers medpagetoday.com/hematologyo…
this is because of vaccines - the HPV vaccine works. It prevents pre cancers which prevents cancers AND by preventing pre cancers - we avoid excisional procedures to treat pre cancers that can result in pregnancy complications. It is all a win. I am an oncologist - I don't want to treat your cervix cancer. I don't want you or your child to ever need me. Prevention is the best cure for cancer.
1
12
29
1,905
23 Sep 2024
Looking forward to helping develop a great meeting!
23 Sep 2024
We are thrilled to announce the Scientific Co-Chairs for #IGCS2025! @LindaMileshkin and @SakethGuntupal1 will oversee the development of the scientific program, ensuring an interdisciplinary, high-quality program in the latest advancements in gynecologic oncology.
1
1
15
747
15 Sep 2024
Great results presented by Oliver Klein #ESMO2024 of MOST CIRCUIT trial showing 50% durable responses in clear cell Gynae cancers with Ipi/Nivo with tox as expected. Great collaboration with @ONJCRI @PeterMacRes @Damien Kee #aussiesonthepodium
10
1,006
15 Sep 2024
Great presentation of the first results from ICON9 showing that adding cedirinib to olaparib maintenance therapy did not improve PFS for women with relapsed platinum sensitive ovarian cancer! So proud to lead the trial for @anzgog who recruited 1/3 of the patients
Don’t miss the presentation from Shibani Nicum on ICON9, a phase III study on maintenance therapy with olaparib and cediranib in relapsed platinum-sensitive ovarian cancer 🌸
@uclcancer | #ESMO2024 | #CRUKFunded
ALT Image of Shibani Nicum
2
11
1,318
Linda Mileshkin retweeted
2 Sep 2024
Extremely honoured our group secured $3M funding for Centre of Research Excellence to improve the quality of survival in gyn cancer patients (ALIVE WELL). Best CRE team with @BaxterEvaL @_SandiHayes @LindaMileshkin @MonikaJanda @KristyRobledo @HaithamTuffaha @GebskiVal @UQ_News
2
8
41
1,606
2 Sep 2024
It was a great honour to be part of this group developing recommendations for how to improve clinical trial research into endometrial cancer in the future. This is much needed given the increasing burden of endometrial cancer in our community. @anzgog @BowtellLab #EDEN
28 Aug 2024
New Policy Review:
Clinical #research in #endometrialcancer: consensus recommendations from the Gynecologic Cancer InterGroup @GCIGTrials thelancet.com/journals/lanon…
2
19
840